Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date: January 16, 2013
Event: Exercise of underwriters' option to purchase additional shares in a public offering.
Key Financial Metrics
This filing reports a specific capital event rather than periodic financial performance. The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
- Shares Purchased: 1,200,000 additional shares of common stock.
- Price Per Share: $20.13.
- Total Proceeds from Option: $24,156,000 (calculated as 1,200,000 shares × $20.13).
Material Changes
The material change reported is the increase in the total number of shares sold in the company's public offering due to the full exercise of the underwriters' option. This event occurred on January 16, 2013.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, risk factors, or contingencies beyond the announcement of the share purchase.
Investor Verification Checklist
- Verify the total gross proceeds from the entire public offering (including the initial tranche and this option exercise).
- Confirm the updated total number of shares outstanding following this issuance.
- Review the attached press release (Exhibit 99.1) for details on the use of proceeds.
- Check subsequent filings for the final closing of the offering and any underwriting discounts or commissions.